JP Morgan Maintains Overweight on Amicus Therapeutics, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Amicus Therapeutics (NASDAQ:FOLD) but lowers the price target from $17 to $16.
August 16, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Amicus Therapeutics but lowers the price target from $17 to $16.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. The net impact is likely neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100